Sequana Medical announces date change for Half Year 2019 Business Update and Financial Results

World News: . []

The management team will host a conference call with a live webcast presentation at 14.00 CEST / 08.00 ET on the day of the results.

The webcast can be accessed by registering . To participate in the Q&A, please dial one of the numbers below, using confirmation code 475648. The webcast and conference call will be conducted in English and a replay will be available on the Company’s shortly thereafter.

Belgium:               +32 2 792 0434

Switzerland:          +41 43 456 9986

The Netherlands:   +31 20 794 8426

U.K.:                    +44 20 3003 2666

U.S.:                    +1 212 999 6659

Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment options for the management of fluid overload due to liver disease, malignant ascites and heart failure.

Sequana Medical's technology is based on its proprietary pump platform, which is applicable across multiple life-threatening disorders. The pump is being commercialised in Europe for the management of refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and malignant ascites. The number of patients with refractory liver ascites is forecast to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis).

Over 700 pump systems have been implanted to date. The pump has been endorsed by key independent third parties in Europe and has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines for decompensated cirrhosis, the German treatment guidelines (DGVS) for complications of liver cirrhosis and the U.K. NICE interventional procedure guidance for treatment of refractory ascites caused by cirrhosis. In January 2019, the U.S. FDA granted Breakthrough Device designation to the pump for the treatment of recurrent or refractory liver ascites. The Company expects to start POSEIDON, the North American pivotal study, in the second half of 2019 to support approval of the pump in recurrent or refractory liver ascites.

Sequana Medical has leveraged its pump experience and is developing pump DSR (Direct Sodium Removal) to deliver a convenient and fully implanted system for DSR therapy, its novel and proprietary approach for the management of volume overload in patients suffering from heart failure. Volume overload is a major clinical problem in heart failure, a condition that results in $13 billion of U.S. hospital admission costs annually.

Data from the first-in-human single dose DSR proof-of-concept study presented at Heart Failure 2019 demonstrated that DSR can result in the removal of large quantities of sodium and fluid in a safe and tolerable manner. The first clinical study of pump DSR in patients with volume overload due to heart failure is expected to start in the second half of 2019.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit .

More news and information about Sequana Medical NV

Published By:

Globe Newswire: 06:00 GMT Wednesday 14th August 2019

Published: .

Search for other references to "sequana" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us